CYP3A4 and metabolic dysfunction-associated steatotic liver disease: NAFLD-associated proinflammatory molecules and oxidative stress downregulate expression and activity of key drug-metabolizing enzymes and transporters, including enzymes in the CYP3A family, the activity of which decreases with steatosis severity and NAFLD progression.